Ellen Border serves as the Group Leader of the Protein Pipeline group within the Discovery Research division at Adaptimmune Ltd., a pioneering company in the field of T-cell therapy based in Oxfordshire, UK. With a robust background in molecular biology and biotechnology, Ellen leads a...
Ellen Border serves as the Group Leader of the Protein Pipeline group within the Discovery Research division at Adaptimmune Ltd., a pioneering company in the field of T-cell therapy based in Oxfordshire, UK. With a robust background in molecular biology and biotechnology, Ellen leads a dynamic team that specializes in recombinant protein expression and engineering, as well as display technologies. Her leadership is pivotal in advancing key projects aimed at developing innovative therapeutic proteins that enhance the efficacy of T-cell therapies.
In her current role, Ellen not only focuses on optimizing protein pipelines but also fosters a culture of people development and team management, ensuring that her team members are equipped with the necessary skills and knowledge to excel in their roles. Her expertise in gene editing and structural biology plays a crucial role in the design and implementation of cutting-edge research initiatives. Additionally, Ellen is currently providing maternity cover for the leadership of the Gene Editing Tools team within Allogeneic Research, where she is leveraging her extensive experience to drive forward projects that explore novel gene editing techniques.
Ellen's proficiency in fluorescence microscopy and site-directed mutagenesis allows her to tackle complex scientific challenges, enabling the development of next-generation therapies. Her commitment to scientific writing and research not only contributes to the advancement of Adaptimmune’s mission but also positions her as a thought leader in the biotechnology sector. Through her multifaceted role, Ellen Border exemplifies the integration of innovation, teamwork, and scientific rigor essential for success in the rapidly evolving landscape of immunotherapy.
